期刊
IMMUNOBIOLOGY
卷 217, 期 1, 页码 54-60出版社
ELSEVIER GMBH
DOI: 10.1016/j.imbio.2011.08.002
关键词
Anti-tumor immunity; Interleukin-17A; Intestine; Knockout mouse; Tumor progression
类别
资金
- Japan Society for Promotion of Science (JSPS)
- Ministry of Education, Culture, Sports, Science and Technology of Japan [20599015]
- Fonds National de la Recherche Scientifique Medicale (FRSM), Belgique
- Grants-in-Aid for Scientific Research [21591668, 21390132, 20599015, 21390303] Funding Source: KAKEN
Interleukin (IL)-17A is a cytokine involved in neutrophilic inflammation but the role of IL-17A in antitumor immunity is controversial because both pro- and anti-tumor activities of IL-17A have been reported. We hypothesized that constitutive expression of IL-17A in intestinal environment modifies tumor growth. To address the issue, mice were inoculated into subserosa of cecum (i.c.) with murine EL4 lymphoma expressing a model tumor antigen, and tumor growth was monitored. IL-17A-producing cells were detected both in tumor mass and in normal intestinal tissue of i.c. tumor-bearing wild type mice. Tumor size in the wild-type mice was significantly higher than that in the cecum of IL-17A gene-knockout mice. Furthermore, anti-IL-17A monoclonal antibody treatment of wild-type mice resulted in decreased tumor size in the cecum. Model tumor-antigen-specific interferon-gamma production was not modified in draining mesenteric lymph node cells in the absence or after neutralization of IL-17A. All the results suggest that constitutive expression of IL-17A in intestine enhances tumor growth, and anti-IL-17A antibody treatment is a candidate of a new anti-tumor immunotherapy against intestinal tumors. (C) 2011 Elsevier GmbH. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据